Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Open-label, Active-controlled, Dose Finding Study to Evaluate the Efficacy and Safety of F-627 Compared to Filgrastim in Women With Breast Cancer Receiving Myelotoxic Chemotherapy.

NCT02521441 is registered in ClinicalTrials.gov with EVIVE Biotechnology as lead sponsor.

NCT NCT02521441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02521441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Open-label, Active-controlled, Dose Finding Study to Evaluate the Efficacy and Safety of F-627 Compared to Filgrastim in Women With Breast Cancer Receiving Myelotoxic Chemotherapy.
Lead sponsor
EVIVE Biotechnology
Phase
Phase 2
Overall status
Completed
Start date
July 3, 2014
Completion date
December 22, 2015
Enrollment
138 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neutropenia